Comment from Labcorp

Summary: Laboratory Corporation of America Holdings (Labcorp) expresses general support for the draft guidance to streamline nonclinical safety studies for oncology pharmaceuticals, particularly in its goal to reduce unnecessary animal use. The company requests additional clarity on the definitions and requirements for "similar" pharmacological activity and weight of evidence risk assessments.